ArticleFrontiers in endocrinology2026
Mining biomarkers for type 2 diabetic nephropathy based on urinary proteomics and metabolomics.
Article in Frontiers in endocrinology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: To evaluate and identify urinary biomarkers for the early diagnosis and staging of diabetic kidney disease (DKD). Methods: This study enrolled 200 participants, including healthy controls (NDM, n=50) and patients with type 2 diabetes. The diabetic patients were stratified by urinary albumin-to-creatinine ratio (ACR) into the following groups: normoalbuminuria (SDM, n=50), microalbuminuria (MADKD, n=50), and macroalbuminuria (ADKD, n=50). Utilizing an integrated multi-dimensional screening strategy, we systematically evaluated traditional urinary protein markers (urinary retinol-binding protein [URBP], urinary immunoglobulin G [UIgG], urinary transferrin [UTRF], urinary alpha-1-microglobulin [Uα1-MG], and urinary beta-2-microglobulin [Uβ2-MG]), 20 urinary amino acids, and urinary proteins identified via high-throughput mass spectrometry. Candidate proteins were validated by ELISA, and their diagnostic performance was assessed using ROC curve analysis, with ACR serving as the practical clinical reference. Results: Among the traditional urinary protein markers, UTRF and UIgG demonstrated excellent diagnostic value, with areas under the curve (AUC) of 0.926 and 0.916, respectively. Among the amino acids, PRO showed the best diagnostic performance (AUC = 0.746). However, when all 20 urinary amino acids were combined into a diagnostic model, it exhibited outstanding diagnostic value (AUC = 0.928), outperforming individual amino acids and even traditional protein markers. From the top 50 proteins identified in the proteomic screening, serpin family A member 1 (SERPINA1) was determined to be a key protein. Subsequent ELISA validation and ROC analysis further confirmed that SERPINA1 possesses outstanding diagnostic capability (AUC = 0.964, 95% CI: 0.936-0.990), significantly outperforming other candidate proteins, namely osteoclast-associated Ig-like receptor (OSCAR), contactin 1 (CNTN1), and CD58 molecule (CD58). Conclusions: Traditional proteins, especially UTRF/UIgG, hold diagnostic value. The 20-amino-acid combination (AUC = 0.928) outperformed them. This study first systematically identifies urinary SERPINA1 as a highly promising DKD biomarker, offering a novel target for early diagnosis and precise management.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.